Rottenburger, Christof http://orcid.org/0000-0003-3338-9959
Hentschel, Michael
Fürstner, Markus
McDougall, Lisa
Kottoros, Danijela
Kaul, Felix
Mansi, Rosalba
Fani, Melpomeni
Vija, A. Hans
Schibli, Roger
Geistlich, Susanne
Behe, Martin
Christ, Emanuel R.
Wild, Damian http://orcid.org/0000-0002-8135-5350
Clinical trials referenced in this document:
Documents that mention this clinical trial
In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study
https://doi.org/10.1186/s13550-024-01101-w
Funding for this research was provided by:
Swiss Cancer Research Foundation (KFS-3170-02-2013)
Nora van Meeuwen Häfliger Stiftung
University of Basel
Article History
Received: 17 January 2024
Accepted: 27 March 2024
First Online: 6 April 2024
Declarations
:
: The study was approved by the ethics committee of Northwest and Central Switzerland (16.01.2014/No. 312/13) and performed in accordance with good clinical practice standards. Patients were recruited between December 2018 and October 2021 in a consecutive order and signed a written informed consent form in accordance with the Declaration of Helsinki.
: Not applicable.
: Martin Béhé and Roger Schibli are inventors of patent application WO 2015/067473, which contents PP-F11N. Patent holder is Paul Scherrer Institute and the patent was licensed from 2019 to 2022 to Debiopharm International SA (Lausanne, Switzerland). No other conflict of interest relevant to this article was reported.